GLOBAL POLICY WILL REMOVE HEADACHES FROM INTERNATIONAL TRAVEL
Led by Saudi Arabia, the Harmonising Air Travel policy will transform the traveler experience by creating a single, trusted source of information on entry requirements for international travelers The global aviation policy has been developed in cooperation with the UN's International Civil Aviation Organization (ICAO) The Harmonising Air Travel policy seeks to boost the recovery of...
ICA to Host 2nd Annual Asia Pacific Healthcare Conference Online
ICA continues to host meetings and keynote speeches online to help converge listed companies and investors, as well as capture insights and the recent development trends in Asia's healthcare arena. HONG KONG, May 9, 2022 /PRNewswire/ -- ICA Group Holdings Limited (ICA), an Asia-based leader in investor relations, financial communications, investor access and IPO advisory, has announced...
AskGene Limited Announces Completion of USD 20 Million Series A Financing Led by Qiming Venture Partners and TF Capital
CAMARILLO, Calif. and NANJING, China, May 9, 2022 /PRNewswire/ -- AskGene Limited ("AskGene"), a clinical-stage biopharmaceutical company focusing on discovery and development of innovative biological drugs, today announced the completion of USD 20 million in Series A financing. The financing was led by Qiming Venture Partners and TF Capital. Proceeds from the financing will be used to advance clinical...
SCG Cell Therapy announces HSA clinical trial approval of TCR-T cell therapy for liver cancer
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer SCG101 is the first TCR-T cell therapy product to receive a multi-regional Investigational New Drug (IND) approval from Singapore's Health Sciences Authority (HSA) and China's National Medical Products Administration (NMPA) for the treatment of HCC APAC accounts for four in five new cases of liver across...
JW Therapeutics to Present Latest Data of Carteyva® at 2022 ASCO Annual Meeting
SHANGHAI, May 9, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that it will present the latest clinical study data for Carteyva® via poster presentations and online publication at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Title: Two-year follow-up result of RELIANCE...
InxMed Raised $15 million in Series B+ Financing to Advance Innovative Therapies to Drug-resistant Cancers
NANJING, China, May 9, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid tumors, today announced that it had completed $15 million in Series B+ Financing. The Series B+ was funded by Hyfinity Investments. InxMed will use the funds to accelerate ongoing...
ExoCoBio Receives Japanese Patent for Alleviating Dermatitis with Adipose Stem Cell-Derived Exosome
To lay a technological foundation for developing exosome-based medicines and cosmetic products for dermatitis treatment To prove the technological feasibility of ExoSCRT™ for the mass-production of the world's best exosomes with high efficacy SEOUL, Korea, May 9, 2022 /PRNewswire/ -- ExoCoBio Inc., one of global top 4 for stem cell exosome industry, announced that it...
Brii Bio Reports Progress on ESG Commitments in Its Inaugural ESG Report
DURHAM, N.C. and BEIJING, May 7, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company," stock code: 2137.HK), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced that it has published its first progress report on Environmental, Social and Governance...
Aravax appoints Dr Brett Haumann to Board of Directors
MELBOURNE, Australia, May 6, 2022 /PRNewswire/ -- Aravax, a clinical stage biotechnology company focused on developing the most advanced novel therapy for peanut allergy, which is designed to be safe, effective, and convenient, today announces the appointment of industry executive Dr Brett Haumann as a non-executive director to its Board of Directors. Dr Haumann is a pharma veteran with...
VolitionRx Limited Schedules First Quarter 2022 Earnings Conference Call and Business Update
Conference call to take place on Thursday May 12 at 08:30 a.m. Eastern TimeCapital Markets Day Friday May 13 at 10:00 a.m. Eastern Time AUSTIN, Texas, May 6, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday May 12, at 08.30 a.m. Eastern Time to discuss its financial and...
